Treatment options for androgen-independent prostate cancer.

James Gulley*, William D. Figg, William L. Dahut

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Patients with recurrent prostate cancer may be treated with androgen deprivation strategies, but most patients will develop androgen-independent prostate cancer (AIPC). Current strategies for treatment of patients who develop AIPC have shown significant palliation, but no definitive increase in survival to date. The results of large chemotherapy trials with survival endpoints are expected soon. In addition, several novel drugs have proceeded through preclinical testing into early clinical trials. These drugs-either alone or in combination-are designed to target strategic pathways to improve survival and quality of life in patients. This article summarizes standard treatment options and promising new drugs and combination therapies under investigation for AIPC.

Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalClinical advances in hematology & oncology : H&O
Issue number1
StatePublished - Jan 2003
Externally publishedYes


Dive into the research topics of 'Treatment options for androgen-independent prostate cancer.'. Together they form a unique fingerprint.

Cite this